|
|
COMMUNIQUÉ DE PRESSE
ERYTECH annonce sa participation à
la Citi 16th Annual BioPharma Conference
Cambridge, MA EtatsUnis et Lyon France, le 30 août 2021 ERYTECH Pharma Nasdaq & Euronext :
ERYP, société biopharmaceutique de stade clinique qui développe des thérapies innovantes en
encapsulant des médicaments dans les globules rouges, annonce... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
ERYTECH to Participate
in the Citi 16th Annual BioPharma Conference
Cambridge, MA U.S. and Lyon France, August 30, 2021 – ERYTECH Pharma Nasdaq & Euronext: ERYP,
a clinicalstage biopharmaceutical company developing innovative therapies by encapsulating therapeutic
drug substances inside red blood cells, today announced its participation... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
ERYTECH Hosting Key Opinion Leader Webinar on
Eryaspase in Pancreatic Cancer
Webinar on Wednesday, September 1st @ 10am ET/4pm CET
Cambridge, MA U.S. and Lyon France, August 24, 2021 – ERYTECH Pharma Nasdaq & Euronext: ERYP,
a clinicalstage biopharmaceutical company, leader in red bloodcell based cancer therapeutics, announced
today... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUÉ DE PRESSE
ERYTECH organise un webinaire, sur eryaspase
dans le cancer du pancréas, avec des leaders dopinion
Tenue du webinaire le mercredi 1er septembre à 16h00, heure de Paris 10am ET
Cambridge, MA EtatsUnis et Lyon France, le 24 août 2021 ERYTECH Pharma Nasdaq & Euronext :
ERYP, société biopharmaceutique de stade clinique qui développe des thérapies... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUÉ DE PRESSE
ERYTECH confirme son intention de déposer une
demande de BLA pour eryaspase dans le traitement des
patients atteints de LAL hypersensible
▪ Réunion avec la FDA américaine ayant permis de clarifier les étapes et les exigences relatives au dépôt
d’une demande de licence biologique BLA pour eryaspase, chez des... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
ERYTECH Confirms Plans To Submit BLA for Eryaspase in
Hypersensitive ALL Patients
▪ Meeting with the U.S. FDA clarified steps and requirements for the submission of a Biologics License
Application BLA for eryaspase for the treatment of ALL patients who developed hypersensitivity
reactions to prior asparaginase therapy, supported by the... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
REPORT ERYTECH’S COMBINED SHAREHOLDERS’
MEETING ON JUNE 25, 2021
SS RELEASE
Lyon France, June 25, 2021 – ERYTECH Pharma Euronext: ERYP Nasdaq: ERYP announced that its 2021
Annual General Meeting was held in Lyon on Friday, June 25, 2021.
At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were... Lire le communiqué |
|
| |
|
| |
